BRIEF—Shionogi's Fetroja still showing worth in treatment-resistant bacterial infections

New data is to be presented by Shionogi on its approved antibiotic Fetroja (cefiderocol) at IDWeek 2022, including new real-world evidence demonstrating the drug’s strong efficacy against some of the most difficult-to-treat gram-negative bacterial infections.

Data from the PROVE review found that Fetroja achieved clinical cure in 63% of patients with acinetobacter baumannii infections and 63% of people with pseudomonas aeruginosa infections.

PROVE is an ongoing international retrospective study assessing real-world outcomes and safety of Fetroja in hospitalized patients with gram-negative bacterial infections. Of the acinetobacter baumannii infections, 96% were resistant to carbapenems and 97% of pseudomonas aeruginosa infections were carbapenem-resistant.

Additionally, in an analysis of early use experience, including compassionate use where patients had limited treatment options, 80% of those treated with Fetroja reported clinical cure for difficult-to-treat gram-negative infections.